Form 4: Biote Corp. Director and 10% Owner Richard Barrera Granted Over 150,000 Stock Options

Richard R. Barrera, a Director and 10% Owner of biote Corp., was granted 150,439 stock options with an exercise price of $3.93, vesting monthly over three years starting July 9, 2025.

Summary

• Richard R. Barrera, a Director and 10% Owner of biote Corp. (BTMD), was granted 150,439 stock options.
• The options have an exercise price of $3.93 per share.
• The transaction date for this grant was June 9, 2025.
• These options will vest in equal monthly installments over a three-year period, commencing on July 9, 2025.
• The vesting is contingent upon Mr. Barrera's continuous service to the company through each vesting date.
• The options have an expiration date of June 8, 2035.
• Following this transaction, Mr. Barrera beneficially owns 150,439 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard compensation practice that aligns insider interests with shareholders, which is generally viewed favorably. However, it doesn't represent new positive financial performance or strategic breakthroughs for the company.

Positives

• The grant of stock options to a Director and 10% Owner, Richard R. Barrera, aligns his interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule over three years encourages continuous service and commitment from a key stakeholder.

Negatives

• The exercise price of $3.93 is a fixed price, meaning the options only have intrinsic value if the stock price rises above this level.
• The grant of options could lead to dilution if exercised, though this is a standard form of equity compensation.

Risks

• The vesting of the stock options is subject to the reporting person's continuous service, meaning the options could be forfeited if service is terminated before full vesting.
• The value of the options is dependent on the future market price of biote Corp.'s Class A Common Stock exceeding the exercise price of $3.93.

Future Outlook

The stock options granted to Richard R. Barrera will vest in equal monthly installments over a three-year period commencing on July 9, 2025, subject to his continuous service. This indicates a future commitment and incentive structure for a key stakeholder.

Industry Context

This Form 4 filing reports an insider transaction, specifically the grant of stock options, which is a common form of equity compensation for directors and executives across various industries, including the biotechnology and healthcare sectors where biote Corp. operates. Such grants are standard practice to align management and director incentives with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to directors and significant owners is a standard practice in corporate governance and executive compensation across industries, including biotechnology and healthcare.
• The three-year vesting period is a common duration for equity awards, designed to encourage long-term commitment and performance, comparable to practices at companies like Moderna (MRNA) or Pfizer (PFE) for their executive and board compensation.
• The exercise price being set at a specific value ($3.93) is typical for non-qualified stock options, where the value is tied to the stock's performance above that price.

Related Party Transactions

• The grant of 150,439 stock options to Richard R. Barrera, a Director and 10% Owner of biote Corp., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grant of options aims to align the interests of a significant director and owner with shareholders, potentially leading to better long-term performance. However, future exercise of these options could lead to minor dilution.

Next Steps

• The stock options will begin vesting in equal monthly installments starting July 9, 2025, over a three-year period.
• Richard R. Barrera's continuous service to biote Corp. is required for the options to vest fully.

Key Dates

Recommendation

Keywords

biote Corp., BTMD, Richard R. Barrera, stock options, equity compensation, Form 4, SEC filing, insider transaction, director compensation, 10% owner